Home/ Stocks/ PHGE

BiomX Inc.

PHGE XASE

$0.63 +0.01 (+1.28%) ▲ 15-min delayed

Open

$0.61

High

$0.63

Low

$0.59

Volume

141.8K

Market Cap

$6.34M

About BiomX Inc.

BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 57 Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2025	N/A	$-36,199,000	$22.19
FY 2025	N/A	$-36,199,000	$22.19
Q3 2025	N/A	$-9,166,000	$0.29
Q1 2025	N/A	$-7,659,000	$0.33

Related Market News

No specific coverage for PHGE yet. Check out our latest market news or earnings calendar.

Get PHGE Alerts

Stay ahead with breaking news, price alerts, and expert analysis on BiomX Inc..

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.